SELARL PHARMACIE VLG 92 : revenue, balance sheet and financial ratios

SELARL PHARMACIE VLG 92 is a French company founded 19 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in VILLENEUVE-LA-GARENNE (92390), this company of category PME shows in 2015 a revenue of 1.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE VLG 92 (SIREN 492269469)
Indicator 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue N/C N/C N/C N/C N/C N/C N/C 1 381 787 € 815 930 €
Net income 258 766 € 70 913 € 167 171 € 41 € -222 906 € 100 153 € 99 689 € -134 430 € -270 442 €
EBITDA N/C N/C N/C N/C N/C N/C N/C 147 265 € -159 781 €
Net margin N/C N/C N/C N/C N/C N/C N/C -9.7% -33.1%

Revenue and income statement

In 2022, SELARL PHARMACIE VLG 92 generates positive net income of 259 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2022) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

258 766 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 148%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 31%. The balance between equity and debt is satisfactory.

Debt ratio (2022) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

147.508%

Financial autonomy (2022) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

31.372%

Asset age ratio (2022) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

31.0%

Solvency indicators evolution
SELARL PHARMACIE VLG 92

Sector positioning

Debt ratio
147.51 2022
2020
2021
2022
Q1: 24.5
Med: 74.73
Q3: 182.59
Average -8 pts over 3 years

In 2022, the debt ratio of SELARL PHARMACIE VLG 92 (147.51) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
31.37% 2022
2020
2021
2022
Q1: 28.53%
Med: 47.06%
Q3: 66.62%
Average

In 2022, the financial autonomy of SELARL PHARMACIE VLG 92 (31.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 300.80. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2022) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

300.8

Liquidity indicators evolution
SELARL PHARMACIE VLG 92

Sector positioning

Liquidity ratio
300.8 2022
2020
2021
2022
Q1: 145.2
Med: 199.49
Q3: 275.01
Excellent

In 2022, the liquidity ratio of SELARL PHARMACIE VLG 92 (300.80) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2022) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2022) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2022) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2022) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELARL PHARMACIE VLG 92

Positioning of SELARL PHARMACIE VLG 92 in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 215 transactions of similar company sales in 2022, the value of SELARL PHARMACIE VLG 92 is estimated at 3 044 772 € (range 2 046 692€ - 4 566 593€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2022
215 transactions
2046k€ 3044k€ 4566k€
3 044 772 € Range: 2 046 692€ - 4 566 593€
NAF 5 année 2022

Valuation method used

Net Income Multiple
258 766 € × 11.8x = 3 044 772 €
Range: 2 046 692€ - 4 566 593€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 215 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE VLG 92 with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE VLG 92

What is the revenue of SELARL PHARMACIE VLG 92 ?

The revenue of SELARL PHARMACIE VLG 92 in 2015 is 1.4 M€.

Is SELARL PHARMACIE VLG 92 profitable?

Yes, SELARL PHARMACIE VLG 92 generated a net profit of 259 k€ in 2022.

Where is the headquarters of SELARL PHARMACIE VLG 92 ?

The headquarters of SELARL PHARMACIE VLG 92 is located in VILLENEUVE-LA-GARENNE (92390), in the department Hauts-de-Seine.

Where to find the tax return of SELARL PHARMACIE VLG 92 ?

The tax return of SELARL PHARMACIE VLG 92 is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE VLG 92 operate?

SELARL PHARMACIE VLG 92 operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.